scp776
Acute Ischemic Stroke
Key Facts
About Silver Creek Pharmaceuticals
Silver Creek Pharmaceuticals is a private, clinical-stage biotech developing novel biologics to rescue cells from injury. Its lead asset, scp776, is a first-in-class, targeted IGF1 fusion protein currently in a Phase II trial for acute ischemic stroke, with preclinical data suggesting potential in heart attack and kidney injury. The company leverages its proprietary 'Smart Growth Factor' platform to design therapies that aim to mitigate secondary tissue damage by inhibiting apoptosis. Leadership includes seasoned drug development executives with experience from Pfizer, Roche, and other biopharma companies.
View full company profileAbout Silver Creek Pharmaceuticals
Silver Creek Pharmaceuticals is a private, clinical-stage biotech developing novel biologics to rescue cells from injury. Its lead asset, scp776, is a first-in-class, targeted IGF1 fusion protein currently in a Phase II trial for acute ischemic stroke, with preclinical data suggesting potential in heart attack and kidney injury. The company leverages its proprietary 'Smart Growth Factor' platform to design therapies that aim to mitigate secondary tissue damage by inhibiting apoptosis. Leadership includes seasoned drug development executives with experience from Pfizer, Roche, and other biopharma companies.
View full company profileAbout Silver Creek Pharmaceuticals
Silver Creek Pharmaceuticals is a private, clinical-stage biotech developing novel biologics to rescue cells from injury. Its lead asset, scp776, is a first-in-class, targeted IGF1 fusion protein currently in a Phase II trial for acute ischemic stroke, with preclinical data suggesting potential in heart attack and kidney injury. The company leverages its proprietary 'Smart Growth Factor' platform to design therapies that aim to mitigate secondary tissue damage by inhibiting apoptosis. Leadership includes seasoned drug development executives with experience from Pfizer, Roche, and other biopharma companies.
View full company profileTherapeutic Areas
Other Acute Ischemic Stroke Drugs
| Drug | Company | Phase |
|---|---|---|
| Presendin™ (Exenatide) | Invex Therapeutics | Phase 2 |
| Supernova Stent Retriever | Gravity Medical Technology | Commercial |
| Neutron Reperfusion Catheter | Gravity Medical Technology | Commercial |
| AST-004 | Astrocyte Pharmaceuticals | Phase 1/2 |
| VB-001 | VST Bio | Pre-clinical |
| Pulse NanoMED for AIS | Euphrates Vascular | Pre-clinical |
| NeVa NET | Vesalio | Development/Commercial |
| ApTOLL | aptaTargets | Phase 2 |
| ThermoSuit® for Acute Ischemic Stroke | Life Recovery Systems HD | Pivotal Trial (Planned) |
| Pulsante for Ischemic Stroke | Realeve | Research/Clinical Study |
| Glenzocimab (ACT017) | Acticor Biotech | Phase 2/3 |
| eTrieve™ Microcatheter | Magneto Thrombectomy Solutions | Phase 1 |